巨子 ICON - 財經股票資訊及專家分析
搜尋 股票

Akebia Therapeutics

AKBA
最少15分鐘延遲,股票資訊由第三方資訊供應商提供
・Akebia Therapeutics - 延遲價格・最後更新於 28/01 12:14
最高位
1.920
最低位
1.770
開市價
--
前收市價
1.820
成交量(千)
123.89
成交額(百萬)
1.39
買入
--
賣出
--
每手股數
--
市值(百萬)
335.92
市盈率
--
息率
--
差價
--
52週高低
5.140 - 1.780
所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱
Akebia Therapeutics
證券代碼
AKBA.US
所屬板塊
Biotechnology
公司業務
Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States.
發行量
174960413
公司總部
245 First Street, Suite 1100
公司網址
http://www.akebia.com
公司電郵
ir@akebia.com
公司電話
+1 617 871-2098
暫無內容

關於

Akebia Therapeutics(AKBA.US)所屬的行業板塊為Biotechnology。
Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States.
詳細公司背景可參考: http://www.akebia.com